Results 51 to 60 of about 3,401,781 (173)
Prophylactic Ruxolitinib for Cytokine Release Syndrome (CRS) in Relapse/Refractory (R/R) AML Patients Treated with Flotetuzumab
Blood, 2020 Introduction: CRS is a potentially life-threatening toxicity observed following T cell-redirecting therapies. CRS is associated with elevated cytokines, including IL6, IFNγ, TNFα, IL2 and GM-CSF. Glucocorticosteroids (GC) and the IL6 receptor blocking antibody tocilizumab (TCZ) can reduce CRS severity; however, CRS may still occur and limit the ...Geoffrey L Uy, Michael P. Rettig, Stephanie Christ, Ibrahim Aldoss, Michael T. Byrne, Harry P. Erba, Martha L. Arellano, Matthew C Foster, John E. Godwin, Farhad Ravandi, Peter H. Sayre, Anjali S Advani, Matthew J. Wieduwilt, Ashkan Emadi, Laura C. Michaelis, Patrick J. Stiff, Martin Wermke, Norbert Vey, Patrice Chevalier, Emmanuel Gyan, Christian Recher, Fabio Ciceri, Matteo Giovanni Carrabba, Antonio Curti, Geert Huls, Max S. Topp, Mojca Jongen-Lavrencic, John Muth, Teia Curtis, Mary Beth Collins, Erin Timmeny, Kuo Guo, Jian Zhao, Kathy Tran, Patrick Kaminker, Priyanka Patel, Ouiam Bakkacha, Kenneth Jacobs, Maya Kostova, Jennifer Seiler, Bob Lowenberg, Sergio Rutella, Roland B. Walter, Ezio Bonvini, Jan K Davidson-Moncada, John F. DiPersio +45 moreopenaire +1 more sourceAn in vitro co-culture model with CAR-T cells, antigen-presenting cells, and tumor cells to evaluate CAR-T cell-induced cytokine release syndrome
Frontiers in Cellular and Infection MicrobiologyObjectiveChimeric antigen receptor (CAR) T-cell therapy has demonstrated remarkable efficacy in hematological malignancies. However, it can also cause severe systemic toxicity, known as cytokine release syndrome (CRS).Yuke Ren, Yuke Ren, Zhi Lin, Shuangxing Li, Ruiqiu Zhang, Ruiqiu Zhang, Zixuan Lai, Zixuan Lai, Hua Jiang, Zhe Qu, Guitao Huo, Di Zhang, Yanwei Yang, Bo Li, Xingchao Geng +14 moredoaj +1 more sourceSeverity of Cytokine Release Syndrome Influences Outcome After Axicabtagene Ciloleucel for Large B cell Lymphoma: Results from the US Lymphoma CAR-T Consortium
, 2022 •Durable responses to axi-cel are seen in patients who do not develop cytokine release syndrome .•In patients receiving axi-cel, grade 1 to 2 cytokine release syndrome is associated with best outcomes.•Patients with grade 3 to 5 experience the worst ...Andreadis, Charalambos, Ghobadi, Armin, Sehgal, Alison, Jacobs, Miriam T., Frederick L. Locke, Jay Y. Spiegel, Matthew Lunning, Loretta J. Nastoupil, Miriam T. Jacobs, Brian T. Hill, Julio C. Chavez, Vose, Julie M., Alison Sehgal, Miklos, David B., David B. Miklos, Yi Lin, Feng Gao, Sattva S. Neelapu, Julie M. Vose, Munoz, Javier, Lin, Yi, Reagan, Patrick M., Lunning, Matthew, Oluwole, Olalekan O., Lazaros Lekakis, Charalambos Andreadis, Jain, Michael D., Dahiya, Saurabh, Andre Goy, Deol, Abhinav, Aaron P. Rapoport, Neelapu, Sattva S., Hill, Brian T., N. Nora Bennani, Spiegel, Jay Y., Rapoport, Aaron P., Abhinav Deol, Locke, Frederick L., McGuirk, Joseph, Patrick M. Reagan, Armin Ghobadi, Gao, Feng, Saurabh Dahiya, Michael D. Jain, Lekakis, Lazaros, Bennani, N. Nora, Nastoupil, Loretta J., Chavez, Julio C., Javier Munoz, Joseph McGuirk, Olalekan O. Oluwole, Goy, Andre +51 morecore +1 more sourceRisk, Characteristics and Biomarkers of Cytokine Release Syndrome in Patients with Relapsed/Refractory AML or MDS Treated with CD3xCD123 Bispecific Antibody APVO436
, 2021 We evaluate the risk, characteristics and biomarkers of treatment-emergent cytokine release syndrome (CRS) in patients with relapsed/refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) who received APVO436 during the dose-escalation Paul J. Shami, Shami, Paul J, Justin Watts, Elizabeth Cull, Mims, Alice S, Lin, Tara L, Cogle, Christopher R, Uckun, Fatih M, Cynthia Lee, Watts, Justin, Tara L. Lin, Patel, Prapti, Eunice Wang, Cull, Elizabeth, Christopher R. Cogle, Fatih M. Uckun, Lee, Cynthia, Prapti Patel, Alice S. Mims, Wang, Eunice +19 morecore +1 more sourceSupplementary Figure S13 from Dissecting the Mechanisms Underlying the Cytokine Release Syndrome (CRS) Mediated by T-Cell Bispecific Antibodies
, 2023 <p>Supplementary Figure S13. A. 3D in vitro experimental setup. Human PBMCs and SU-DHL-8 tumor cells were co-cultured in a ratio of 5:1 and treated with 0.01 nM CD20-TCB in the presence or absence of 5 μg/mL adalimumab for 24 hrs. Supernatant from the co-cultures was transferred to the bottom channel of the Mimetas OrganoPlate®.Marina Bacac, Pablo Umana, Christian Klein, Hélène Haegel, Katerina Apostolopoulou, Floriana Cremasco, Marlene Biehl, Roberta Bianchi, Sylvia Jenni, Stefanie Briner, Johannes Sam, Petra Schwalie, Petra Gerber, Stephan Schmeing, Sylvia Herter, Tamara Hüsser, Emilio Yángüez, Emily Piccione, Sabrina Danilin, Sina Nassiri, Llucia Albertí-Servera, Nathalie Steinhoff, Gabrielle Leclercq-Cohen +22 moreopenaire +1 more sourceSupplementary Table S3 from Dissecting the Mechanisms Underlying the Cytokine Release Syndrome (CRS) Mediated by T-Cell Bispecific Antibodies
, 2023 <p>Supplementary Table S3. Specification of reagents for flow cytometry (HUVEC staining)</p>Marina Bacac, Pablo Umaña, Christian Klein, Hélène Haegel, Katerina Apostolopoulou, Floriana Cremasco, Marlene Biehl, Roberta Bianchi, Sylvia Jenni, Stefanie Briner, Johannes Sam, Petra Schwalie, Petra Gerber, Stephan Schmeing, Sylvia Herter, Tamara Hüsser, Emilio Yángüez, Emily Piccione, Sabrina Danilin, Sina Nassiri, Llucia Albertí Servera, Nathalie Steinhoff, Gabrielle Leclercq-Cohen +22 moreopenaire +1 more sourceSupplementary Figure S11 from Dissecting the Mechanisms Underlying the Cytokine Release Syndrome (CRS) Mediated by T-Cell Bispecific Antibodies
, 2023 <p>Supplementary Figure S11. Single cell RNA-sequencing of whole blood treated with 0.2 μg/mL CD20-TCB was performed using the BD Rhapsody platform. A. UMAP plots of neutrophils colored by treatment. B. UMAP plots showing IL-1β (IL1B), IL-1Ra (IL1RN), IL-6 (IL6), IP-10 (CXCL10), IL-8 (CXCL8), TNF-α (TNF), MCP-1 (CCL2), MIP-1α (CCL3), MIP-1β (CCL4)Marina Bacac, Pablo Umana, Christian Klein, Hélène Haegel, Katerina Apostolopoulou, Floriana Cremasco, Marlene Biehl, Roberta Bianchi, Sylvia Jenni, Stefanie Briner, Johannes Sam, Petra Schwalie, Petra Gerber, Stephan Schmeing, Sylvia Herter, Tamara Hüsser, Emilio Yángüez, Emily Piccione, Sabrina Danilin, Sina Nassiri, Llucia Albertí-Servera, Nathalie Steinhoff, Gabrielle Leclercq-Cohen +22 moreopenaire +1 more source